Jiangsu Recbio Technology and Shenzhen Rhegen Biotech established a joint JV to pool their knowledge of mRNA vaccine technology. Recbio has built a portfolio of 11 vaccine candidates, while Rhegen believes it has the world’s leading mRNA technology. Rhegen has developed three technology platforms for mRNA vaccines. The JV plans to apply the latest mRNA knowledge and novel adjuvant technology to develop a next-gen COVID-19 vaccine along with vaccines for other major infectious diseases and therapeutic cancer vaccines. Recbio’s 11 vaccine candidates target a broad spectrum of diseases, including cervical cancer, COVID-19, adult tuberculosis, shingles, hand-foot-and-mouth-disease and influenza. One year ago, Recbio raised $227 million to develop its portfolio of candidates. Recbio has established three technology platforms including a novel adjuvants platform, a protein engineering platform and an immunological evaluation platform. Since the company’s start, the development of novel adjuvants has become an essential development strategy. It is one of the few companies globally to develop novel human adjuvants to benchmark all of the FDA-approved adjuvants (AS01, AS03, AS04, CpG, and MF59). Rhegen Bio is committed to the development of nucleic acid biomedical products and treatment methods such as mRNA. It has four novel platform technologies: target protein structure design, mRNA modification, mRNA synthesis and next-gen delivery. Rhegen believes it can design and develop highly accessible mRNA vaccines and therapeutic biological drugs from beginning to approval stage.
For further information, see ChinaBio Today (http://www.chinabiotoday.com/articles/recbio-rhegen-mrna)
